Athersys, Inc. is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company's MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients. In the neurological area, the Company evaluated in a completed Phase II trial, the potential for MultiStem treatment of patients with a history of neurological damage from an ischemic stroke. The Company initiated a Phase II clinical study in the United States for the administration of MultiStem cell therapy to patients with a history of an acute myocardial infarction, or AMI.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:ATHX
- CUSIP: N/A
- Web: www.athersys.com
Capitalization:- Market Cap: $180.33 million
- Outstanding Shares: 111,316,000
Average Prices:- 50 Day Moving Avg: $1.58
- 200 Day Moving Avg: $1.41
- 52 Week Range: $1.02 - $2.30
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -5.06
- P/E Growth: -0.22
Sales & Book Value:- Annual Revenue: $3.36 million
- Price / Sales: 53.67
- Book Value: $0.26 per share
- Price / Book: 6.23
Profitability:- EBIDTA: ($28,340,000.00)
- Net Margins: -765.65%
- Return on Equity: -135.04%
- Return on Assets: -95.38%
Debt:- Current Ratio: 4.15%
- Quick Ratio: 4.15%
Misc:- Average Volume: 602,810 shs.
- Beta: -0.19
- Short Ratio: 9.38
Frequently Asked Questions for Athersys (NASDAQ:ATHX)
What is Athersys' stock symbol?
Athersys trades on the NASDAQ under the ticker symbol "ATHX."
How were Athersys' earnings last quarter?
Athersys, Inc. (NASDAQ:ATHX) issued its quarterly earnings results on Tuesday, May, 9th. The company reported ($0.06) EPS for the quarter, topping the Zacks' consensus estimate of ($0.07) by $0.01. The company earned $1.50 million during the quarter, compared to analysts' expectations of $0.45 million. Athersys had a negative return on equity of 135.04% and a negative net margin of 765.65%. The firm's revenue was down 90.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.06 EPS. View Athersys' Earnings History.
When will Athersys make its next earnings announcement?
Where is Athersys' stock going? Where will Athersys' stock price be in 2017?
3 analysts have issued 12-month price targets for Athersys' stock. Their predictions range from $7.00 to $9.00. On average, they anticipate Athersys' share price to reach $8.00 in the next year. View Analyst Ratings for Athersys.
What are analysts saying about Athersys stock?
Here are some recent quotes from research analysts about Athersys stock:
- 1. Maxim Group analysts commented, "Athersys spent $5.6M in the quarter and ended the period with $32M in cash at the end of the period (which includes $21M from a capital raise in February). This capital should support the company for the next year. Lonza: Athersys manufacturing partner completed a manufacturing review that has now paved the way for product to be supplied for pivotal trials (including Healio’s Treasure trial). Partnering: Looking for partners now for MultiStem." (5/10/2017)
- 2. According to Zacks Investment Research, "Athersys is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The company's lead product candidate, ATHX-105, is an oral, selective 5HT2c receptor agonist in Phase I clinical trials for the treatment of obesity. The company is also developing other orally active pharmaceutical product candidates for the treatment of metabolic and central nervous system disorders, utilizing proprietary technologies, including Random Activation of Gene Expression (RAGE). Athersys is developing MultiStem(r), its patented, adult-derived ``off the shelf'' stem cell product platform, for multiple disease indications, including damage caused by myocardial infarction, bone marrow transplantation/oncology support, ischemic stroke and other indications. " (3/14/2017)
- 3. Needham & Company LLC analysts commented, "Athersys is developing MultiStem, an off-the-shelf cell therapy that promotes tissue repair. The lead indication is ischemic stroke. Existing stroke treatments, which focus on removing the offending blood clot, can only be used in a short window of time, but MultiStem has shown efficacy in a longer time window (24-36 hours) and can thus address far more patients. Athersys' Japanese partner Healios will start a 220-patient pivotal trial shortly. Data is expected in mid-2018. While there is some controversy around the Phase II data, we believe the trial has a favorable risk:reward in what we see as a blockbuster opportunity. Initiate at Buy with a $7 price target." (2/7/2017)
Who are some of Athersys' key competitors?
Some companies that are related to Athersys include BioSpecifics Technologies Corp (BSTC), Ra Pharmctl (RARX), Merus N.V. (MRUS), Edge Therapeutics (EDGE), BioTime (BTX), Rigel Pharmaceuticals (RIGL), Corbus Pharmaceuticals Holdings (CRBP), Immune Design Corp. (IMDZ), GlycoMimetics (GLYC), Minerva Neurosciences (NERV), AVEO Pharmaceuticals (AVEO), DURECT Corporation (DRRX), Ardelyx (ARDX), Oxford BioMedica plc (OXB), Catalyst Pharmaceuticals (CPRX), Akebia Therapeutics (AKBA), Circassia Pharmaceuticals PLC (CIR) and Chimerix (CMRX).
Who are Athersys' key executives?
Athersys' management team includes the folowing people:
- Gil Van Bokkelen Ph.D., Chairman of the Board, Chief Executive Officer
- William Lehmann Jr, President, Chief Operating Officer
- John J. Harrington Ph.D., Executive Vice President, Chief Scientific Officer, Director
- Robert J. Deans Ph.D., Executive Vice President - Regenerative Medicine
- Laura K. Campbell CPA, Vice President - Finance
- Lee E. Babiss Ph.D., Lead Independent Director
- Ismail Kola, Independent Director
- Lorin Jeffry Randall, Independent Director
- Jack L. Wyszomierski, Independent Director
Who owns Athersys stock?
Athersys' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include NEXT Financial Group Inc (0.09%). Company insiders that own Athersys stock include Bokkelen Gil Van, Ismail Kola, John J Harrington, Laura K Campbell, William Lehmann Jr and William Lehmann, Jr. View Institutional Ownership Trends for Athersys.
Who bought Athersys stock? Who is buying Athersys stock?
Athersys' stock was acquired by a variety of institutional investors in the last quarter, including NEXT Financial Group Inc. Company insiders that have bought Athersys stock in the last two years include Ismail Kola and Laura K Campbell. View Insider Buying and Selling for Athersys.
How do I buy Athersys stock?
Shares of Athersys can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Athersys' stock price today?
One share of Athersys stock can currently be purchased for approximately $1.62.
MarketBeat Community Rating for Athersys (NASDAQ ATHX)MarketBeat's community ratings are surveys of what our community members think about Athersys and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Athersys (NASDAQ:ATHX)Earnings History by Quarter for Athersys (NASDAQ ATHX)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/9/2017 | | ($0.06) | | | | | N/A |  |
| 5/9/2017 | Q1 2017 | ($0.07) | ($0.06) | $0.45 million | $1.50 million | View | Listen | |
| 3/9/2017 | Q4 2016 | ($0.08) | ($0.10) | $0.45 million | $0.98 million | View | Listen | |
| 11/9/2016 | Q3 2016 | ($0.10) | ($0.07) | $0.60 million | $0.31 million | View | Listen | |
| 8/9/2016 | Q216 | ($0.10) | ($0.08) | $0.32 million | $0.60 million | View | N/A | |
| 5/5/2016 | Q1 | ($0.08) | $0.06 | $1.85 million | $15.45 million | View | N/A | |
| 3/10/2016 | Q4 | ($0.09) | $0.04 | $3.72 million | $10.61 million | View | Listen | |
| 11/5/2015 | Q315 | ($0.07) | ($0.08) | $1.75 million | $0.40 million | View | Listen | |
| 8/6/2015 | Q2 | ($0.08) | $0.02 | $2.66 million | $0.22 million | View | N/A | |
| 5/11/2015 | Q115 | ($0.07) | ($0.16) | $2.01 million | $0.73 million | View | Listen | |
| 3/12/2015 | Q414 | ($0.09) | ($0.08) | $0.50 million | $0.24 million | View | N/A | |
| 11/10/2014 | Q314 | ($0.09) | ($0.11) | $0.54 million | $0.29 million | View | N/A | |
| 8/11/2014 | Q214 | ($0.09) | ($0.06) | $0.70 million | $0.40 million | View | N/A | |
| 5/8/2014 | Q114 | ($0.10) | ($0.09) | $0.66 million | $0.71 million | View | N/A | |
| 3/13/2014 | Q413 | ($0.11) | ($0.15) | $1.81 million | $0.92 million | View | N/A | |
| 11/14/2013 | Q3 | ($0.12) | ($0.10) | $0.49 million | $0.62 million | View | Listen | |
| 8/13/2013 | Q2 2013 | ($0.12) | ($0.11) | $390.00 million | $0.57 million | View | N/A | |
| 5/14/2013 | Q1 2013 | ($0.11) | ($0.18) | $1.58 million | $0.33 million | View | N/A | |
| 11/8/2012 | Q312 | ($0.13) | ($0.12) | $2.51 million | $1.00 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Athersys (NASDAQ:ATHX)2017 EPS Consensus Estimate: ($0.27)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | ($0.07) | ($0.07) | ($0.07) |
| Q2 2017 | 2 | ($0.07) | ($0.06) | ($0.07) |
| Q3 2017 | 2 | ($0.07) | ($0.06) | ($0.07) |
| Q4 2017 | 2 | ($0.07) | ($0.06) | ($0.07) |
(Data provided by Zacks Investment Research)
Dividend History for Athersys (NASDAQ:ATHX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Athersys (NASDAQ:ATHX)Insider Ownership Percentage: 9.40%
Institutional Ownership Percentage: 17.75%
Insider Trades by Quarter for Athersys (NASDAQ:ATHX)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 6/16/2017 | John J Harrington | EVP | Sell | 36,000 | $1.45 | $52,200.00 | |
| 2/1/2017 | Ismail Kola | Director | Buy | 15,000 | $1.01 | $15,150.00 | |
| 2/1/2017 | Laura K Campbell | Insider | Buy | 20,000 | $1.01 | $20,200.00 | |
| 12/19/2016 | William Lehmann Jr | Insider | Sell | 3,000 | $1.60 | $4,800.00 | |
| 12/16/2016 | John J Harrington | EVP | Sell | 15,000 | $1.60 | $24,000.00 | |
| 9/19/2016 | William Lehmann Jr | Insider | Sell | 3,000 | $1.96 | $5,880.00 | |
| 9/16/2016 | John J Harrington | EVP | Sell | 15,000 | $1.96 | $29,400.00 | |
| 6/21/2016 | William Lehmann Jr | COO | Sell | 25,000 | $2.17 | $54,250.00 | |
| 3/21/2016 | William Lehmann Jr | COO | Sell | 25,000 | $2.41 | $60,250.00 | |
| 12/21/2015 | William Lehmann, Jr. | COO | Sell | 25,000 | $1.03 | $25,750.00 | |
| 9/21/2015 | Bokkelen Gil Van | CEO | Sell | 9,500 | $1.36 | $12,920.00 | |
| 9/21/2015 | John J. Harrington | EVP | Sell | 8,150 | $1.36 | $11,084.00 | |
| 9/21/2015 | William Lehmann, Jr. | COO | Sell | 25,000 | $1.36 | $34,000.00 | |
| 6/22/2015 | William Lehmann Jr | COO | Sell | 25,000 | $1.21 | $30,250.00 | |
| 6/19/2015 | John J Harrington | Insider | Sell | 8,150 | $1.23 | $10,024.50 | |
| 6/19/2015 | Robert J Deans | EVP | Sell | 5,080 | $1.23 | $6,248.40 | |
| 6/9/2015 | Kenneth H Traub | Director | Buy | 30,000 | $1.27 | $38,100.00 | |
| 3/20/2015 | William Lehmann Jr | COO | Sell | 25,000 | $3.14 | $78,500.00 | |
| 3/19/2015 | Bokkelen Gil Van | CEO | Sell | 9,500 | $3.10 | $29,450.00 | |
| 3/19/2015 | Robert J Deans | EVP | Sell | 5,080 | $3.10 | $15,748.00 | |
| 12/19/2014 | Bokkelen Gil Van | CEO | Sell | 9,500 | $1.29 | $12,255.00 | |
| 12/19/2014 | Robert J Deans | EVP | Sell | 5,080 | $1.28 | $6,502.40 | |
| 12/19/2014 | William Lehmann Jr | COO | Sell | 30,000 | $1.29 | $38,700.00 | |
| 9/24/2014 | Kenneth H Traub | Director | Buy | 30,000 | $1.39 | $41,700.00 | |
| 9/22/2014 | William Lehmann Jr | COO | Sell | 30,000 | $1.40 | $42,000.00 | |
| 9/19/2014 | Bokkelen Gil Van | CEO | Sell | 9,500 | $1.41 | $13,395.00 | |
| 9/19/2014 | John J Harrington | Insider | Sell | 8,150 | $1.41 | $11,491.50 | |
| 9/19/2014 | Robert J Deans | EVP | Sell | 5,080 | $1.41 | $7,162.80 | |
| 8/18/2014 | Lorin Randall | Director | Sell | 15,000 | $1.54 | $23,100.00 | |
| 6/20/2014 | William Lehmann Jr | COO | Sell | 12,000 | $1.58 | $18,960.00 | |
| 6/19/2014 | Bokkelen Gil Van | CEO | Sell | 9,500 | $1.63 | $15,485.00 | |
| 6/19/2014 | John J Harrington | Insider | Sell | 8,150 | $1.63 | $13,284.50 | |
| 6/19/2014 | Robert J Deans | EVP | Sell | 5,080 | $1.63 | $8,280.40 | |
| 6/19/2014 | William Lehmann Jr | COO | Sell | 13,000 | $1.62 | $21,060.00 | |
| 3/20/2014 | William Lehmann Jr | COO | Sell | 25,000 | $3.62 | $90,500.00 | |
| 3/18/2014 | Bokkelen Gil Van | CEO | Sell | 9,500 | $3.54 | $33,630.00 | |
| 3/18/2014 | John J Harrington | Insider | Sell | 8,150 | $3.54 | $28,851.00 | |
| 3/18/2014 | Robert J Deans | EVP | Sell | 5,080 | $3.54 | $17,983.20 | |
| 12/20/2013 | William Lehmann Jr | COO | Sell | 25,000 | $2.13 | $53,250.00 | |
| 12/11/2013 | Kenneth H Traub | Director | Buy | 20,000 | $1.94 | $38,800.00 | |
| 9/20/2013 | John J Harrington | Insider | Sell | 30,000 | $1.82 | $54,600.00 | |
| 9/20/2013 | William Lehmann Jr | COO | Sell | 12,000 | $1.83 | $21,960.00 | |
| 11/28/2012 | Laura K Campbell | VP | Buy | 10,000 | $1.01 | $10,100.00 | |
| 11/15/2012 | Robert J Deans | EVP | Buy | 3,500 | $0.99 | $3,465.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Athersys (NASDAQ:ATHX)
Latest Headlines for Athersys (NASDAQ:ATHX)
| Source: |
|
| Date | Headline |
|---|
 | Athersys to Host Second Quarter Financial Results Call - GlobeNewswire (press release)
globenewswire.com - July 10 at 4:10 PM |
 | Athersys to Host Second Quarter Financial Results Call
finance.yahoo.com - July 10 at 4:10 PM |
 | Athersys, Inc. (NASDAQ:ATHX) Receives Consensus Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - July 10 at 2:30 PM |
| ETFs with exposure to Athersys, Inc. : July 7, 2017
finance.yahoo.com - July 8 at 7:02 AM |
 | Athersys And Aurinia Target Human And Animal Health - Seeking Alpha
seekingalpha.com - June 27 at 3:50 PM |
| Athersys, Inc. (ATHX) Receives Consensus Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - June 23 at 8:56 AM |
| Athersys, Inc. (ATHX) EVP John J. Harrington Sells 36,000 Shares
www.americanbankingnews.com - June 19 at 7:57 PM |
 | Why Athersys, Inc. (ATHX) Could Be Positioned for a Surge - Nasdaq
www.nasdaq.com - June 9 at 2:28 AM |
| Why Athersys, Inc. (ATHX) Could Be Positioned for a Surge
finance.yahoo.com - June 8 at 4:24 PM |
| Zacks: Athersys, Inc. (ATHX) Receives Consensus Recommendation of "Strong Buy" from Analysts
www.americanbankingnews.com - June 8 at 8:16 AM |
| Upcoming Short- And Long-Term Catalysts For Athersys - Seeking Alpha
seekingalpha.com - May 31 at 3:41 PM |
| Zacks: Athersys, Inc. (ATHX) Given Average Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - May 24 at 4:30 PM |
| Maxim Group Reiterates $9.00 Price Target for Athersys, Inc. (ATHX)
www.americanbankingnews.com - May 17 at 7:10 PM |
| Athersys Poised For Lucrative Stem Cell Stroke Partnership This Year
seekingalpha.com - May 16 at 12:30 PM |
| ETFs with exposure to Athersys, Inc. : May 15, 2017
finance.yahoo.com - May 15 at 4:11 PM |
| Athersys, Inc. (ATHX) Given "Buy" Rating at Maxim Group
www.americanbankingnews.com - May 14 at 4:00 PM |
| Athersys, Inc. :ATHX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017
finance.yahoo.com - May 12 at 4:14 PM |
| Athersys, Inc. (ATHX) to Post Q2 2017 Earnings of ($0.06) Per Share, William Blair Forecasts
www.americanbankingnews.com - May 12 at 10:40 AM |
| Athersys beats by $0.01, beats on revenue
seekingalpha.com - May 11 at 9:11 PM |
| Equities Analysts Issue Forecasts for Athersys, Inc.'s FY2019 Earnings (ATHX)
www.americanbankingnews.com - May 11 at 3:20 PM |
| Edited Transcript of ATHX earnings conference call or presentation 9-May-17 8:30pm GMT
finance.yahoo.com - May 10 at 8:55 PM |
| Athersys, Inc. (ATHX) Posts Earnings Results, Beats Expectations By $0.01 EPS
www.americanbankingnews.com - May 9 at 9:42 PM |
| Athersys Reports First Quarter 2017 Results
finance.yahoo.com - May 9 at 8:44 PM |
| Athersys, Inc. (ATHX) Downgraded by Zacks Investment Research
www.americanbankingnews.com - May 9 at 4:38 PM |
| Athersys, Inc. (ATHX)
finance.yahoo.com - May 8 at 8:38 PM |
| Athersys, Inc. (ATHX) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - May 7 at 7:12 AM |
| Analysts Set $9.00 Target Price for Athersys, Inc. (ATHX)
www.americanbankingnews.com - May 5 at 9:18 AM |
| Athersys (ATHX) Given Daily Coverage Optimism Score of 0.03
www.americanbankingnews.com - May 4 at 4:22 PM |
| Athersys (ATHX) Earning Positive Media Coverage, Report Shows
www.americanbankingnews.com - May 1 at 12:38 PM |
| Short Interest in Athersys, Inc. (ATHX) Grows By 129.9%
www.americanbankingnews.com - April 27 at 7:06 AM |
| Athersys (ATHX) Earns Daily Coverage Optimism Score of 0.22
www.americanbankingnews.com - April 26 at 4:52 PM |
| Athersys (ATHX) Given Daily News Sentiment Rating of 0.17
www.americanbankingnews.com - April 23 at 10:16 AM |
| Athersys, Inc. (ATHX) Given $9.00 Average Target Price by Analysts
www.americanbankingnews.com - April 20 at 11:25 AM |
| Athersys (ATHX) Given News Sentiment Rating of 0.16
www.americanbankingnews.com - April 20 at 8:29 AM |
| Athersys: Initiating Coverage With Buy Rating And Price Target Of $8
seekingalpha.com - April 19 at 4:00 PM |
| Short Interest in Athersys, Inc. (ATHX) Decreases By 11.4%
www.americanbankingnews.com - April 18 at 12:54 PM |
| Athersys (ATHX) Earns Daily News Sentiment Rating of 0.24
www.americanbankingnews.com - April 17 at 4:04 PM |
| Athersys to Host First Quarter Financial Results Call
finance.yahoo.com - April 10 at 3:40 PM |
| Zacks: Analysts Set $9.00 Price Target for Athersys, Inc. (ATHX)
www.americanbankingnews.com - April 5 at 9:31 AM |
| William Blair Reaffirms "Outperform" Rating for Athersys, Inc. (ATHX)
www.americanbankingnews.com - April 3 at 8:32 AM |
 | Here's What Might Be Pushing Up Shares of Athersys, Inc. Today
www.fool.com - March 31 at 3:49 PM |
| Can the Rally in Athersys (ATHX) Shares Continue?
finance.yahoo.com - March 31 at 3:49 PM |
| Athersys, Inc. (ATHX) to Post Q1 2017 Earnings of ($0.07) Per Share, William Blair Forecasts
www.americanbankingnews.com - March 31 at 12:05 PM |
| Is the Options Market Predicting a Spike in Athersys (ATHX) Stock?
finance.yahoo.com - March 30 at 4:07 PM |
| Tonix Pharmaceuticals and Athersys Advance as FDA Clinical Trials Move Forward
finance.yahoo.com - March 30 at 4:07 PM |
| Athersys to Present at Needham Healthcare Conference on April 4
finance.yahoo.com - March 29 at 8:53 PM |
 | Athersys (ATHX) Stock Rallies as William Blair Initiates Coverage
www.investopedia.com - March 29 at 8:53 PM |
| Athersys, Inc. (ATHX) Now Covered by Analysts at William Blair
www.americanbankingnews.com - March 28 at 6:42 PM |
| Athersys, Inc. (ATHX) Given a $9.00 Price Target by Maxim Group Analysts
www.americanbankingnews.com - March 21 at 3:40 PM |
| Brokerages Expect Athersys, Inc. (ATHX) to Post ($0.06) EPS
www.americanbankingnews.com - March 21 at 11:52 AM |
Athersys (ATHX) Chart for Thursday, July, 27, 2017
